Abstract
Background
Evidence from previous studies has suggested that ginger extract exhibits the potential as an alternative treatment for Coronavirus disease 2019 (COVID-19). Here, we want to investigate whether ginger supplement improves the clinical manifestation of hospitalized COVID-19 individuals.
Methods
A total of 227 hospitalized individuals with COVID-19 were randomized to either the control (n = 132) or intervention group (n = 95). The intervention group took ginger supplement orally at the dosage of 1.5 g twice daily, until they were discharged from the hospital. Both groups received the same standard of general medical care during hospitalization, and the length of stay was recorded and compared between groups.
Results
Among all participants, a significant reduction in hospitalization time (the difference between the treatment and control groups was 2.4 d, 95% CI 1.6–3.2) was detected in response to the ginger supplement. This effect was more pronounced in men, participants aged 60 years or older, and participants with pre-existing medical conditions, relative to their counterparts (P-interactions < 0.05 for all).
Conclusion
Ginger supplement significantly shortened the length of stay of hospitalized individuals with COVID-19.
Trial registration: The trial was registered on the Chinese Clinical Trial Registry (ChiCTR2200059824).
Keywords: COVID-19, Hospital length of stay, Ginger, Randomized control trial
Background
Coronavirus disease 2019 (COVID-19) is an infectious disease induced by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). As one of the largest pandemics in recent centuries, as of August 2022, COVID-19 has caused more than 590 million cases, including over 6 million deaths; continuously challenging the global health system, increasing medical burdens and severely threatening people’s lives. While immunization with vaccines proved the efficacy of protecting people from virus infection [1, 2], with the emerging new strains of the virus and decay of antibodies after vaccination [3, 4], the risk of infection could increase [5]. Therefore, finding effective interventions to help people recover from COVID-19 is of equal importance as building up immunity via vaccination.
Ginger (Zingiber officinale), as an edible plant, is also considered as a traditional herbal medicine in China. Scientific evidence has demonstrated that ginger has broad anti-inflammatory properties through modulating cytokine production and other regulatory pathways [6–9]. Specifically, ginger exhibited a protective role against acute respiratory distress syndrome [10, 11], the primary cause of mortality in severe COVID-19 cases. Moreover, bioactive compounds present in ginger, such as gingerol and shogaol, showed high affinity to the SARS-CoV-2 spike protein, thus could potentially interfere with the spike protein and host angiotensin-converting enzyme 2 (ACE-2) interaction [12, 13]. Interactions between ginger-derived compounds and papain-like protease and other virus proteins essential for its survival were also indicated via computational theoretical models [14, 15].
Taken together, ginger presents the potential as an alternative therapeutic agent to treat COVID-19. Therefore, we conducted a clinical trial to examine the effect of the ginger supplement on the clinical manifestations of individuals with COVID-19.
Methods
Study design and participants
The study protocol was approved by the institutional review boards of Zhongshan Hospital, Fudan University, and the trial was registered on the Chinese Clinical Trial Registry (ChiCTR2200059824). All participants provided written informed consent. Study participants were recruited among the individuals with COVID-19 hospitalized at two Fangcang shelter hospitals, from April to May 2022, in Shanghai, China. At the time of admission, individuals with COVID-19 tested positive but no symptoms (asymptomatic infection) were invited to participate in the study.
Sample-size estimation
As our study is experimental in nature with no prior reference to estimate the sample size for treatment effect testing, we made our best effort to recruit eligible participants and obtain an acceptable sample size.
Randomization and masking
Eligible participants were randomized to either the ginger supplement group or the control group, and no masking was implemented in the current trial.
Intervention
The ginger supplements [Fujian Longzhi Biotechnology Co., Ltd (Fujian, China)] were provided in the form of ginger powder packed individually (1.5 g/bag), participants in the ginger supplement group were asked to mix it with hot water and take it orally at the dosage one bag per time twice daily (before breakfast and lunch), the intervention continued until the participants were discharged from the hospital. The standard for hospital discharge was their throat swab test for COVID-19 reached 35 (CT value) for consecutive 2 days without major symptoms, including but not limited to sore throat, stuffy nose, fever, and cough. Both groups received the same general medical care during the hospitalization period.
Outcome
The primary outcome was the length of stay before participants were recovered and discharged from hospitals, where they had repeated negative results of COVID-19 tests and were cleared of COVID-19 as judged by the physicians in charge.
Statistical analyses
Descriptive statistics are presented as means ± SDs or numbers (percentages) for numeric and categorical variables, respectively. Baseline characteristics between groups were compared using t-test or χ2 tests when appropriate. Generalized linear models were used to analyze the effect of ginger supplement adjusted for age, sex, location, chronic disease status (hypertension, diabetes, other chronic diseases), and surgical history. To examine whether the potential effects of the ginger supplement on hospitalization time were modified by other factors, we tested the interaction between sex and intervention, age and intervention, and pre-existing medical conditions (combined data of diseases status and surgical history) and intervention by adding the interaction component in our model, adjusting for aforementioned covariates. Subgroup analyses were subsequently conducted when the interaction terms were significant. All analyses were performed using SAS version 9.4 (SAS Institute Inc), and a 2-sided P value < 0.05 was considered statistically significant.
Role of funding source
The funding source did not play any role in study design, data collection, analyses, manuscript preparation, or decision to submit the work for publication.
Results
From April to May 2022, a total of 254 participants were recruited from two Fangcang shelter hospitals, and 227 completed the intervention. The baseline characteristics of these participants are shown in Table 1. Except for a relatively higher proportion of individuals with hypertension in the control group (P = 0.05), the sex and age distribution and other basic health conditions were the similar between two groups.
Table 1.
Baseline Participants Characterristics
| Characteristics | Control group (n = 132) | Ginger treatment group (n = 95) |
|---|---|---|
| Men, no. (%) | 85 (64) | 62 (65) |
| Age, y | 56 ± 17 | 53 ± 13 |
| Hypertension, no. (%) | 39 (30) | 17 (18)* |
| Diabetes, no. (%) | 17 (13) | 7 (7) |
| Other chronic diseases, no. (%) | 25 (19) | 11 (12) |
| Surgical history, no. (%) | 9 (7) | 2 (2) |
Data are presented as means ± SDs or numbers (percentages)
*Indicates statistical significance, P = 0.05
The ginger-supplemented group showed a significantly shorter hospitalization time compared with the control (6.0 vs. 8.5 d, P < 0.0001), with an estimated difference of 2.4 d [95% CI 1.6–3.2 d] (Table 2).
Table 2.
Primary and secondary outcomes for control and ginger-supplemented intervention group
| Outcomes | Model estimated | Mean (95% CI) | Intervention difference estimate (95% CI) | P value |
|---|---|---|---|---|
| Control | Ginger | |||
| Primary outcome | ||||
| Participants, no (%) | 132 (58) | 95 (42) | ||
| Unadjusted means, d | 8.5 (8.0–9.0) | 6.1 (5.5–6.7) | 2.4 (1.6–3.2) | < 0.0001 |
| Adjusted means, d | 8.5 (7.9–9.0) | 6.0 (5.4–6.7) | 2.4 (1.6–3.2) | < 0.0001 |
| By sex1 | ||||
| Men (n = 147) | ||||
| Length of stay, d | 8.9 (8.2–9.5) | 5.8 (5.0–6.6) | 3.0 (2.1–4.0) | < 0.0001 |
| Women (n = 80) | ||||
| Length of stay, d | 7.8 (6.9–8.8) | 6.7 (5.5–7.8) | 1.2 (-0.26–2.6) | 0.11 |
| By Age2 | ||||
| Age < 60 (n = 143) | ||||
| Length of stay, d | 7.8 (7.1–8.5) | 6.6 (5.9–7.4) | 1.2 (0.28–2.1) | 0.010 |
| Age ≥ 60 (n = 84) | ||||
| Length of stay, d | 9.9 (9.0–10.7) | 4.9 (3.8–6.1) | 4.9 (3.5–6.4) | < 0.0001 |
| By prior medical conditions3 | ||||
| W/prior medical conditions (n = 87) | ||||
| Length of stay, d | 9.6 (8.9–10.4) | 5.8 (4.7–6.9) | 3.8 (2.5–5.2) | < 0.0001 |
| W/O prior medical conditions (n = 140) | ||||
| Length of stay, d | 7.9 (7.1–8.6) | 6.1 (5.3–6.8) | 1.8 (0.80–2.8) | 0.0005 |
Results were adjusted for sex, age, and prior medical conditions, including hypertension, diabetes, other chronic diseases, and surgical history, as needed
1P-interaction was 0.04 for sex, 0.004 for age, and 0.035 for the status of prior medical conditions
The effects of the ginger supplement on COVID-19 appeared to be modified by sex, age, and prior medical status (P-interaction < 0.05 for all; Table 2). While ginger supplement significantly shortened the length of stay by 3 days [95% CI 2.1–4.0 d] in men (5.8 vs. 8.9 d, P < 0.0001), this beneficial effect was not observed in women (6.7 vs. 7.8 d, P = 0.11). Further, when categorized by age groups, compared to their counterparts, both age groups benefited from the ginger supplement; especially for the participants aged 60 years or older, an almost 5-day [4.9 d, 95% CI 3.5–6.4 d] reduction in hospitalization time was estimated (P < 0.0001). Additionally, when classified by prior medical conditions, ginger-supplemented participants showed significant improvement in hospital stays regardless of their prior health status; where the estimated difference was 3.8 days [95% CI 2.5–5.2 d] in individuals with prior medical conditions and 1.8 days [95% CI 0.8–2.8 d] in participants without pre-existing medical conditions, respectively.
Discussion
To our knowledge, this is the first clinical trial focusing on the effect of the ginger supplement on the clinical manifestation, evaluated as the length of hospital stays, of hospitalized individuals with COVID-19. A significant improvement in hospitalization time was observed in response to the ginger supplement. One possible explanation for the observed beneficial effect of the ginger supplement on the length of stay in study participants could be the ginger-derived exosomal micro-RNA, which has been demonstrated to inhibit lung inflammation caused by COVID-19 in both in vitro and in vivo studies [16].
Interestingly, when stratified by sex, only men benefited from the ginger supplement, whereas no intervention effect was detected in women. This result aligned with the observed differences in manifestation and severity of COVID-19 between men and women reported in previous studies [17, 18], while the underlying mechanism regarding the sex differences in immunopathogenesis needs further investigation, these studies implied a possible difference in the host immunity related to sex and suggesting the necessity of considering potential sex effect in future clinical studies. Besides, our subgroup analysis highlighted the importance of ginger supplement to older adults, where the hospitalization time could be shortened to less than half of their un-supplemented comparisons, which could effectively reduce the suffering and pain and improve the life quality of the elderly. Aging has been recognized as a critical risk factor for the severity and mortality of COVID-19 [19, 20], possibly due to age-related general decline in immune function. Therefore, the beneficial effect of the ginger supplement on the length of hospital stay could be less prominent in younger adults given their relatively quicker recovery compared to the elderly. Last but not the least, we explored the potential impact of pre-existing medical conditions when infected with COVID-19. While the participants with prior health issues tended to have longer hospital stays, supplementing with ginger significantly shortened the length of stay by about 40%, suggesting a strong protective effect of ginger supplement to this vulnerable group.
This study has several limitations. The primary outcome we focused on here is the length of stay in the hospital, it would be better to record other clinical symptoms of COVID-19 to evaluate the potential impact of ginger supplementation on other aspects of the clinical manifestation of COVID-19. Thus this study should be considered preliminary. Further, biological samples (such as blood) were not collected in the current study, and we cannot link the observed difference in hospitalization time to possible changes in the immune response. The future study thus could examine the circulating level of inflammatory biomarkers, and further investigate the underlying mechanism of the observed beneficial effect of the ginger supplement.
In conclusion, this preliminary study suggested that supplementing individuals with COVID-19 with ginger could be a cost-effective strategy in the future treatment of COVID-19, and emphasized the importance of implementing ginger supplementation to the target population to achieve the best outcomes.
Acknowledgements
We thank all the individuals that participated in the current study. We thank Fujian Longzhi Biotechnology Co., Ltd (Fujian, China), Longyan Charity Federation, Shanghai Jinqiao Biyun Charity Foundation, and ZHENYUE Capital for their support.
Abbreviations
- COVID-19
Coronavirus disease 2019
- ACE-2
Angiotensin-converting enzyme 2
Author contributions
D.Y., W.G., X.G., C.B., Y.S., and Z.S. designed and conducted the trial; W.G. assisted in organizing the trial; Y.L. and X.G. performed data analysis and prepared the manuscript; M.J., H. F., Z.Y., H.Q., and Y.Z. provided clinical support, and refined surveys; L.X. and H.W. assisted in data interpretation and manuscript writing. All authors have read and agreed to the published version of the manuscript. All authors read and approved the final manuscript.
Funding
This research was funded by the National Natural Science Foundation of China (81971863, 82170110), Shanghai Natural Science Foundation (22ZR1444700), Shanghai Pujiang Program (20PJ1402400), Science and Technology Commission of Shanghai Municipality (20DZ2261200), Shanghai Municipal Science and Technology Major Project (ZD2021CY001), and Shanghai Municipal Key Clinical Specialty (shslczdzk02201).
Availability of data and materials
The data that support the findings of this study are available from the corresponding authors upon reasonable request.
Declarations
Ethics approval and consent to participate
The study protocol was approved by the institutional review boards of Zhongshan Hospital, Fudan University, and the trial was registered on the Chinese Clinical Trial Registry (ChiCTR2200059824). All participants provided written informed consent.
Consent for publication
Not applicable.
Competing interests
The authors declare that they have no competing interests.
Footnotes
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Yaqi Li, Dawei Yang and Xiwen Gao equally contributed to this work
Contributor Information
Zhirong Sun, Email: sunrongsun@aliyun.com.
Wenye Geng, Email: drug@fudan.edu.cn.
Xiang Gao, Email: Xiang_Gao@fudan.edu.cn.
References
- 1.Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection. Nat Med. 2021;27(7):1205–1211. doi: 10.1038/s41591-021-01377-8. [DOI] [PubMed] [Google Scholar]
- 2.Goel RR, Painter MM, Apostolidis SA, Mathew D, Meng W, Rosenfeld AM, et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern. Science. 2021;374(6572):abm0829. doi: 10.1126/science.abm0829. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Pegu A, O'Connell SE, Schmidt SD, O'Dell S, Talana CA, Lai L, et al. Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants. Science. 2021;373(6561):1372–1377. doi: 10.1126/science.abj4176. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4.Naaber P, Tserel L, Kangro K, Sepp E, Jurjenson V, Adamson A, et al. Dynamics of antibody response to BNT162b2 vaccine after six months: a longitudinal prospective study. Lancet Reg Health Eur. 2021;10:100208. doi: 10.1016/j.lanepe.2021.100208. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N Engl J Med. 2020;383(27):2603–2615. doi: 10.1056/NEJMoa2034577. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Zehsaz F, Farhangi N, Mirheidari L. The effect of Zingiber officinale R. rhizomes (ginger) on plasma pro-inflammatory cytokine levels in well-trained male endurance runners. Cent Eur J Immunol. 2014;39(2):174–80. doi: 10.5114/ceji.2014.43719. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Grzanna R, Lindmark L, Frondoza CG. Ginger–an herbal medicinal product with broad anti-inflammatory actions. J Med Food. 2005;8(2):125–132. doi: 10.1089/jmf.2005.8.125. [DOI] [PubMed] [Google Scholar]
- 8.Aggarwal BB, Shishodia S. Suppression of the nuclear factor-kappaB activation pathway by spice-derived phytochemicals: reasoning for seasoning. Ann N. Y. Acad Sci. 2004;1030:434–441. doi: 10.1196/annals.1329.054. [DOI] [PubMed] [Google Scholar]
- 9.Ezzat SM, Ezzat MI, Okba MM, Menze ET, Abdel-Naim AB. The hidden mechanism beyond ginger (Zingiber officinale Rosc.) potent in vivo and in vitro anti-inflammatory activity. J Ethnopharmacol. 2018;214:113–23. doi: 10.1016/j.jep.2017.12.019. [DOI] [PubMed] [Google Scholar]
- 10.Xie X, Sun S, Zhong W, Soromou LW, Zhou X, Wei M, et al. Zingerone attenuates lipopolysaccharide-induced acute lung injury in mice. Int Immunopharmacol. 2014;19(1):103–109. doi: 10.1016/j.intimp.2013.12.028. [DOI] [PubMed] [Google Scholar]
- 11.Vahdat Shariatpanahi Z, Mokhtari M, Taleban FA, Alavi F, Salehi Surmaghi MH, Mehrabi Y, et al. Effect of enteral feeding with ginger extract in acute respiratory distress syndrome. J Crit Care. 2013;28(2):217. e1–6. doi: 10.1016/j.jcrc.2012.04.017. [DOI] [PubMed] [Google Scholar]
- 12.Ahkam AH, Hermanto FE, Alamsyah A, Aliyyah IH, Fatchiyah F. Virtual prediction of antiviral potential of ginger (Zingiber officinale) bioactive compounds against spike and MPro of SARS-CoV2 protein. Berk Penelit Hayati J Biol Res. 2020;25(2):52–57. [Google Scholar]
- 13.Haridas M, Sasidhar V, Nath P, Abhithaj J, Sabu A, Rammanohar P. Compounds of citrus medica and Zingiber officinale for COVID-19 inhibition: in silico evidence for cues from Ayurveda. Futur J Pharm Sci. 2021;7(1):13. doi: 10.1186/s43094-020-00171-6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 14.Goswami D, Kumar M, Ghosh SK, Das A. Natural product compounds in alpinia officinarum and ginger are potent SARS-CoV-2 papain-like protease inhibitors. 2020.
- 15.Oso BJ, Adeoye AO, Olaoye IF. Pharmacoinformatics and hypothetical studies on allicin, curcumin, and gingerol as potential candidates against COVID-19-associated proteases. J Biomol Struct Dyn. 2022;40(1):389–400. doi: 10.1080/07391102.2020.1813630. [DOI] [PubMed] [Google Scholar]
- 16.Teng Y, Xu F, Zhang X, Mu J, Sayed M, Hu X, et al. Plant-derived exosomal microRNAs inhibit lung inflammation induced by exosomes SARS-CoV-2 Nsp12. Mol Ther. 2021;29(8):2424–2440. doi: 10.1016/j.ymthe.2021.05.005. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Bunders MJ, Altfeld M. Implications of sex differences in immunity for SARS-CoV-2 pathogenesis and design of therapeutic interventions. Immunity. 2020;53(3):487–495. doi: 10.1016/j.immuni.2020.08.003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 18.Scully EP, Haverfield J, Ursin RL, Tannenbaum C, Klein SL. Considering how biological sex impacts immune responses and COVID-19 outcomes. Nat Rev Immunol. 2020;20(7):442–447. doi: 10.1038/s41577-020-0348-8. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242. doi: 10.1001/jama.2020.2648. [DOI] [PubMed] [Google Scholar]
- 20.Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062. doi: 10.1016/S0140-6736(20)30566-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Data Availability Statement
The data that support the findings of this study are available from the corresponding authors upon reasonable request.